As a pioneer in our field, we have gained a lot of critical know-how and experience since our incorporation in 1989. This expertise is our most valuable asset. And we attach great importance to increasing our expertise through our commitment to technical competence, diligence and reliability.
As an open and learning organization, Microsynth endeavors to conduct a constant dialogue with renowned experts, universities and research institutions. We assume far-ranging responsibility for our stakeholders. Last but not least, we are committed to sustainable development and to the protection of the natural resources of our planet. Through constant adherence to this philosophy, Microsynth has become an internationally acclaimed company in the field of molecular biology.
Facts & Figures
|Addresses & Locations
Microsynth Austria GmbH
P.O Box only!
P.O Box only!
|Ownership||Microsynth AG is a privately held company|
|Business Size||Small to Medium Enterprise (SME)|
|Quality Management||Microsynth AG: ISO 9001:2008 and ISO 17025:2005 (STS 429; i.e. the Sanger sequencing and genotyping laboratories)
Microsynth Austria GmbH: ISO 9001:2008
||Incorporation of Microsynth AG. The initial focus of the company is on providing DNA oligonucleotide synthesis services to academic institutes and companies in Switzerland. The founder, Dr. Tobias Schmidheini, is considered one of the pioneers in this exciting area of molecular biology.|
||The company offers Sanger DNA sequencing services as additional main pillar of Microsynth’s business|
||Investment in real-time PCR, with an initial focus on offering GMO analysis services|
||DNA genotyping services, with a special focus on paternity validation|
||Completion of a major building expansion to accommodate the growing number of employees and to provide a modern lab and office infrastructure. The entire building is constructed as a Minergie building. Minergie is a sustainable building standard that is recognized globally for its effectiveness in achieving lower energy and resource consumption.|
|2007||Investment in the 454 GS FLX System from Roche to offer our customers customized services in the area of next-generation sequencing|
||Successful participation in a ring trial for the detection of Bovine Virus Diarrhoe (BVD), utilizing an unparalleled high-throughput real-time PCR system. More than 320’000 samples were tested from October 1, 2008 until December 31, 2008.|
|2009||Microsynth celebrates its 20th anniversary|
|2010||Microsynth invests in SOLiD 4 and 5500xl SOLiD Systems from Life Technologies to strengthen its DNA Sequencing Platform|
|2011||Investment in fully automated, high-throughput DNA/RNA extraction technology|
|2012||Incorporation of Microsynth Austria GmbH with the goal to become a major sequencing player in the Austrian market
Expansion of the NGS business unit by acquiring the MiSeq Illumina system and building up a bioinformatics department
|2013||Microsynth merges with Seqlab GmbH, one of the leading sequencing companies in Germany, to better access Europe's largest life science market|
|2014||Further strengthening of the NGS/Bioinformatics department by aquiring the NextSeq system from Illumina|